Teva is introducing a first generic of Revlimid (lenalidomide capsules) in dosage strengths of 5 mg, 10 mg, 15 mg and 25 mg.
[Read more: Teva debuts generic Narcan]
Teva’s lenalidomide capsules are used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes and mantle cell lymphoma following specific prior treatment.
“The launch of our first generic version of Revlimid in the U.S. provides patients with another important treatment option for these extremely challenging conditions, demonstrating Teva’s commitment to making complex generic drugs available to the patients who need them,” Christine Baeder, senior vice president, chief operating officer of U.S. Generics at Teva USA, said. “This product adds to our broad generic portfolio of oncology treatments, which accounts for 73% of the essential medicines in this category, as defined by the World Health Organization.”
[Read more: Teva launches 1st generic of Absorica]
Revlimid had a market value of $2.3 billion as of December 2021, according to IQVIA data.